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Hedgehog (Hh)-Patched1 (Ptch1) signaling plays
essential roles in various developmental processes,
but little is known about its role in postnatal homeo-
stasis. Here, we demonstrate regulation of postnatal
bone homeostasis by Hh-Ptch1 signaling. Ptch1-de-
ficient (Ptch1+/) mice and patients with nevoid basal
cell carcinoma syndrome showed high bone mass in
adults. In culture, Ptch1+/ cells showed accelerated
osteoblast differentiation, enhanced responsiveness
to the runt-related transcription factor 2 (Runx2), and
reduced generation of the repressor form of Gli3
(Gli3rep). Gli3rep inhibited DNA binding by Runx2 in
vitro, suggesting a mechanism that could contribute
to the bone phenotypes seen in the Ptch1 heterozy-
gotes. Moreover, systemic administration of the Hh
signaling inhibitor cyclopamine decreased bone
mass in adult mice. These data provide evidence
that Hh-Ptch1 signaling plays a crucial role in postna-
tal bone homeostasis and point to Hh-Ptch1 signal-
ing as a potential molecular target for the treatment
of osteoporosis.
INTRODUCTION
Hh-Ptch1 signaling is a highly conserved pathway, and its activ-
ities are central to the patterning and morphogenesis of many
different regions within the bodies of vertebrates and insects
(Ingham and McMahon, 2001). In the conventional model of Hh
signal transduction, Smoothened (Smo), a seven-pass trans-
membrane protein, has an intrinsic intracellular signaling activity
that is repressed by Patched (Ptch). Ptch is a 12-pass transmem-
brane receptor of Hh, and two Ptch genes, Ptch1 and Ptch2,
have been identified in vertebrates. The binding of Hh ligands
to Ptch relieves Ptch’s repressive effect on Smo, initiating Hh-Ptch1 signal transduction. In vertebrates, intracellular signaling
activity is mediated through the zinc finger transcription factors
Gli1, Gli2, and Gli3 (Ingham and McMahon, 2001). Hh-Ptch1 sig-
naling suppresses the processing of Gli2 and Gli3 into transcrip-
tional repressor forms. Gli2 is suggested to function primarily as
a transcriptional activator, and Gli3 as a transcriptional repres-
sor, although some studies have shown the opposite (Ingham
and McMahon, 2001). On the other hand, Gli1 is one of the tran-
scriptional targets of Hh-Ptch1 signaling and functions as a
strong transcriptional activator (Ingham and McMahon, 2001).
Hh-Ptch1 signaling exerts its diverse and potent activities
through such complicated regulations of Gli proteins.
We and others have clarified the essential roles of Hh-Ptch1
signaling in bone development through analyses of Ihh-deficient
mice (Ihh/) (St-Jacques et al., 1999), Ihh//wild-type (WT) chi-
meric mice (Chung et al., 2001), and Smo-deficient (Smo/)/WT
chimeric mice (Long et al., 2004). These results revealed that lo-
cal production of Ihh by hypertrophic chondrocytes and direct
input of Ihh to osteoblast precursors are required for bone forma-
tion. Gli1 is not essential for initial Hh signal transduction and is
dispensable for mouse development (Park et al., 2000), but
loss of Gli2 or Gli3 in mice results in severe skeletal and neural
defects and embryonic or perinatal lethality (Hui and Joyner,
1993; Mo et al., 1997). Removal of Gli3 in Shh/ mice rescues
a multitude of defects in limb patterning (Litingtung et al.,
2002), and removal of Gli3 in Ihh/ mice partially rescues
defects in osteoblast development (Hilton et al., 2005). Further-
more, Hh-regulated processing of Gli3 has an important role in
developing limbs (Wang et al., 2000). These lines of evidence
suggest that Gli3 is a critical mediator of Hh activity, especially
in skeletal development. This idea is further supported by analy-
sis of Greig cephalopolysyndactyly syndrome (GCPS) and Pallis-
ter-Hall syndrome (PHS), two autosomal dominant syndromes
associated with different types of mutations in the GLI3 locus.
Although GCPS and PHS are distinct clinical entities with numer-
ous nonoverlapping features, both syndromes manifest similar
skeletal abnormalities including preaxial polydactyly (Johnston
et al., 2005). Furthermore, nevoid basal cell carcinoma syndromeDevelopmental Cell 14, 689–699, May 2008 ª2008 Elsevier Inc. 689
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syndrome associated with PTCH1 haploinsufficiency, is also
characterized by skeletal abnormalities partly similar to those
of GCPS and PHS (Gorlin, 1987). These lines of evidence sug-
gest that the repressive effect of PTCH1 and GLI3 on Hh-
Ptch1 signaling has a crucial role in the skeletal system.
Ptch1 has emerged as a tumor suppressor gene and develop-
mental regulator. Homozygous Ptch1-deficient (Ptch1/) mice
die at around day 9.5 of embryogenesis with neural tube defects,
and derepression of Hh target genes occurs as a consequence
of ectopic activation of Smo (Goodrich et al., 1997). Heterozy-
gous Ptch1-deficient (Ptch1+/) mice have features that partly
recapitulate those of NBCCS (Goodrich et al., 1997). The pa-
tients are characterized by skeletal abnormalities, craniofacial
abnormalities, large body size, and tumors, including basal cell
carcinomas of the skin and cerebellar medulloblastomas (Gorlin,
1987). Studies of Ptch1+/ mice have established the roles of
Hh-Ptch1 signaling in tumorigenesis (Goodrich et al., 1997; Wet-
more et al., 2000), body size determination, and limb patterning
(Goodrich et al., 1997; Milenkovic et al., 1999). Despite these
extensive studies, little is known about the involvement of
Ptch1 in bone formation and postnatal bone homeostasis. It
also remains unclear which transcriptional factors are involved
in the control of osteoblast differentiation downstream of Hh-
Ptch1 signaling.
This study aimed to determine the physiological function of
Hh-Ptch1 signaling in postnatal bone homeostasis, and to clarify
the underlying molecular mechanisms, focusing particularly on
transcriptional regulation of osteogenesis-related genes.
RESULTS
Ptch1 Haploinsufficiency Increases Bone Mass In Vivo
Ptch1/ mice died between embryonic days (E) 9.0 and 10.5
(Goodrich et al., 1997); so to investigate the physiological role
of Ptch1 in bone metabolism, we analyzed the skeletal system
in Ptch1+/ mice at 8 weeks of age. Ptch1+/ mice grew without
gross skeletal abnormalities, and X-ray and 3D-CT analyses of
femurs and tibias revealed that Ptch1+/ mice had increased
bone mass compared to the wild-type littermates (WT) (Fig-
ure 1A). The bone mineral density (BMD) of these bones was sig-
nificantly increased in Ptch1+/ mice (Figure 1B). von Kossa
staining and calcein double labeling of the tibias revealed an in-
crease in trabecular bone mass due to accelerated bone forma-
tion in Ptch1+/ mice, whereas toluidine blue staining revealed
no obvious abnormalities in the epiphyseal plates (Figure 1C).
Bone histomorphometric analyses revealed that parameters for
bone formation were markedly increased in Ptch1+/ mice (Fig-
ure 1D), suggesting that Ptch1 haploinsufficiency enhances
osteoblast differentiation and matrix synthesis. Ptch1+/ mice
also had greater numbers of tartrate-resistant acid phosphatase
(TRAP)-positive osteoclasts (Figure 1E), and all parameters of
bone resorption were significantly increased in Ptch1+/ mice
(Figure 1F). Accelerated osteogenesis was also observed in
E17.5 Ptch1+/ embryos without gross abnormalities in skeletal
patterning or differentiation of growth plate chondrocytes (Fig-
ures S1A–S1C; see the Supplemental Data available with
this article online). These results suggest that Ptch1 haploinsuf-
ficiency causes high bone mass in adult mice due to an690 Developmental Cell 14, 689–699, May 2008 ª2008 Elsevier Inc.increase in bone formation, and this phenotype starts at the
fetal stage.
The phenotype ofPtch1+/mice, amodel for NBCCS, led us to
ask whether or not bone mass was affected in NBCCS patients.
We had the opportunity to measure BMDs of the lumbar spine
and femoral neck in two patients (one male, one female). They
had been diagnosed as having NBCCS based on diagnostic
criteria (Gorlin, 1987) or on the identification of mutations in
the PTCH1 gene (Fujii et al., 2003a, 2003b). When compared
to age- and gender-matched controls, the patients had high
BMDs (Table S1). The serum level of bone-specific ALP and
the urine level of deoxypyridinolines of the male patient were
markedly elevated (Table S1), suggesting increased bone
metabolism. This finding in NBCCS patients is consistent with
the phenotypes observed in Ptch1+/ mice.
Ptch1 Haploinsufficiency Enhances Osteoblast
Differentiation In Vitro
To identify which cells contribute to the skeletal phenotype
of Ptch1+/ mice, we performed ex vivo cultures of primary
bone cells from WT and Ptch1+/ mice. There was no significant
difference in cell proliferation of bone marrow stromal cells
(BMSCs) and osteoblast precursors (OPs) between Ptch1+/
and WT (Figure S2). However, osteoblast differentiation was
accelerated by Ptch1 haploinsufficiency in both cell types, as
indicated by the enhancement of alkaline phosphatase (ALP)
activity and calcified nodule formation (Figures 2A and 2B) and
by upregulation of osteoblast marker gene expression (Figures
2C and 2D).
Endogenous BMPs have crucial roles in bone formation (Hoff-
mann and Gross, 2001), and Runx2 is essential for both endo-
chondral and intramembranous bone development (Ducy et al.,
1997; Komori et al., 1997). In addition, we and others reported
that BMP signaling and Runx2 synergistically work as potent in-
ducers of osteoblast differentiation (Bae et al., 2007; Ohba et al.,
2007; Phimphilai et al., 2006; Yang et al., 2003). Furthermore,
two recent studies highlighted novel mechanisms underlying
the Hh/Gli2- and Hh/Gli3-mediated osteoblast differentiation,
focusing on regulation of BMP2 expression (Zhao et al., 2006;
Garrett et al., 2003), induction of Runx2 expression, and regula-
tion of Runx2 function (Shimoyama et al., 2007). In light of these
reports, to gain insight into mechanisms underlying accelerated
osteoblast differentiation in Ptch1+/, we investigated the ex-
pression of Runx2 and Bmp2, 4, 6, and 7. As shown in Figures
2E–2G, there were no obvious differences in the mRNA expres-
sion of Runx2, the protein expression of Runx2, or the mRNA
expression of Bmps between Ptch1+/ and WT cells. However,
the response to exogenously introduced Runx2 and to recombi-
nant humanBMP2 (rhBMP2)wasmarkedly enhanced inPtch1+/
cells (Figure 2H). These data suggest that Ptch1 haploinsuffi-
ciency enhances osteoblast differentiation by augmenting
Runx2 and/or BMP/Smad signaling, but not by inducing the
expression of Runx2 and Bmps.
We also examined the role of Ptch1 in osteoclast differentia-
tion and found that osteoclast precursors including primary
bone marrow macrophages (BMMf) and RAW264.7 cells ex-
pressed Ptch1 mRNA (Figure S3A). Coculture of calvarial OPs
and BMMf showed that osteoclastogenesis was enhanced
when OPs, but not BMMf, were derived from Ptch1+/ mice
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of nuclear factor-kB ligand (Rankl) was markedly upregulated
in Ptch1+/ OPs, whereas that of osteoprotegerin was not
(Figure S3C). These results suggest that the enhanced bone re-
sorption in Ptch1+/ mice was a secondary effect of increased
osteoblast activity, and that upregulation of Rankl was at least
partly responsible for mediating the effect.
Ptch1 Haploinsufficiency Causes Activation
of Hh Signaling and Alters Expression
of Gli3 in Osteoblast Precursors
To explore downstream mediators of Ptch1 haploinsufficiency,
we examined the effect of Ptch1 haploinsufficiency on Hh-
Ptch1 signaling in cultured OPs. Expression of Ptch1 mRNA
Figure 1. Radiological and Histological
Analyses of Adult WT and Ptch1+/ Litter-
mates
(A) Plain X-ray images of the whole bodies, femurs
and tibias, and three-dimensional CT images of
the medial tibias of representative 8-week-old
WT and Ptch1+/ mice.
(B) Bone mineral density of the whole femurs and
tibias from 8-week-old WT and Ptch1+/ mice.
Data are means ± SDs of ten mice per genotype.
*p < 0.05 versus WT.
(C) von Kossa staining, toluidine blue staining, and
calcein double labeling of the proximal tibia
sections of representative 8-week-old WT and
Ptch1+/ mice. Bar, 300 mm.
(D) Histomorphometric analyses of bone volume
and bone formation parameters in the proximal
tibias of 8-week-old WT and Ptch1+/ mice. BV/
TV, trabecular bone volume per tissue volume;
Tb. Th, trabecular thickness; Tb. N., trabecular
number; OS/BS, osteoid surface per bone
surface; MAR, mineral apposition rate; BFR bone
formation rate per bone surface.
(E) TRAP staining of the proximal tibia sections of
representative 8-week-old WT and Ptch1+/
mice. Bar, 300 mm.
(F) Histomorphometric analyses of bone resorp-
tion parameters in the proximal tibia. N. Oc/B.
Pm, number of osteoclasts per 100 mm of bone
perimeter; ES/BS, eroded surface per bone sur-
face; Oc. S/BS, osteoclast surface per bone
surface. For (D) and (F), data are means ± SDs
of five mice per genotype. *p < 0.05 versus WT.
was reduced in Ptch1+/ cells (Figure 3A).
Gli1mRNA, a readout of Hh-Ptch1 signal-
ing, was upregulated in Ptch1+/ OPs
(Figure 3A), suggesting that Ptch1 hap-
loinsufficiency led to constitutive activa-
tion of Hh signaling. Hh signaling has
beendemonstrated to suppressGli3 tran-
scription and processing in mouse limb
bud cells (Wang et al., 2000) as well as
Gli2 processing and degradation in
mouse embryonic fibroblasts (Pan et al.,
2006). Based on these reports, we inves-
tigated the expression patterns of Gli2
and Gli3 in Ptch1+/ and WT OPs. Expression of Gli3 mRNA
(Figure 3A), that of Gli3 proteins, and the processing of the full-
length forms of Gli3 (Gli3-190, Gli3full) into the repressor form
of Gli3 (Gli-83, Gli3rep) were markedly reduced in Ptch1+/ OPs
(Figure 3B). Furthermore, Gli3rep, but not Gli3full, preferentially
accumulated in the nucleus and colocalized with Runx2
(Figure 3C), which itself was not altered by Ptch1 haploinsuffi-
ciency (data not shown). By contrast, mRNA expression of Gli2
was not noticeably altered, and no alteration in Gli2 expression,
processing, or localization was detected (Figure 3A and Fig-
ure S4). These results suggest that Ptch1 haploinsufficiency
causes constitutive activation of Hh signaling and represses the
generation of Gli3rep, which may interact with osteogenesis-
related transcription factors such as Runx2 in the nucleus.Developmental Cell 14, 689–699, May 2008 ª2008 Elsevier Inc. 691
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by Competitively Inhibiting DNA Binding of Runx2
The data so far suggest that Gli3 acts as a key downstream me-
diator of Hh-Ptch1 signaling-induced osteoblast differentiation.
To test this hypothesis, we investigated the effect of loss or over-
expression of Gli3 on osteoblast differentiation. Hh signaling-
induced osteoblast differentiation was compared between
Gli3Xt-J/Xt-J (Gli3/) and WT calvarial cells (Hui and Joyner,
1993). ALP activity and calcification of WT cells were enhanced
upon treatment with a Hh agonist (Hh-ago) (Figure 4A). InGli3/
cells, ALP activity and calcification were remarkably enhanced
without Hh-ago treatment, and the treatment with Hh-ago had
little further effect (Figure 4A). In contrast, overexpression of
Gli3rep, but not that ofGli3full, decreasedosteocalcin expression
inWTcells (Figure 4B). These data support the above hypothesis.
Figure 2. Osteoblast Differentiation in
Cultures of Precursor Cells from WT
and Ptch1+/ Littermates
(A and B) ALP and von Kossa staining in osteo-
genic cultures of BMSCs (A) and OPs (B). For
ALP staining, cells were cultured for 10 days. For
von Kossa staining, cells were cultured for 20
days. Representative pictures of independent
experiments are shown.
(C and D) mRNA expression of osteoblast marker
genes in 20-day osteogenic cultures of BMSCs
(C) and OPs (D). mRNA expression was analyzed
by real-time RT-PCR analysis. Alp, alkaline phos-
phatase; Bsp, bone sialoprotein; Oc, osteocalcin.
(E) Runx2 mRNA expression determined by real-
time RT-PCR analysis in 20-day osteogenic
cultures of BMSCs and OPs.
(F) Protein expression of endogenous Runx2 in
OPs cultured for 20 days. Protein expression
was analyzed by immunoblot analysis using spe-
cific antibodies. IB, immunoblot.
(G)mRNA expression ofBmps determined by real-
time RT-PCR analysis in 20-day osteogenic
cultures of OPs.
(H) Osteocalcin mRNA expression determined by
real-time RT-PCR analysis in osteogenic culture
of BMSCs. Cells were infected with adenoviruses
expressing GFP or Runx2; or treated with or with-
out recombinant human BMP2 and cultured for 7
days. For (C)–(E), (G), and (H), data are means ±
SDs of triplicate wells, and representative data of
independent experiments are shown.
They also suggest that Gli3 functions as
a potent repressor of osteoblast differen-
tiation and that, of the two different forms,
Gli3rep plays a central role. Furthermore,
Gli3rep downregulated Runx2-depen-
dent expression of osteocalcin in
C3H10T1/2 cells without affecting protein
levels of Runx2 (Figure 4B and Figure S5).
In addition, the loss or overexpression of
Gli3rep in osteoblasts did not affect pro-
tein expression of osteogenesis-related
transcription factors and cofactors in-
cluding Smad1, Smad2/3, Osterix, LEF,
b-catenin, Runx2, and Cbfb (Figure S6). These results raised
the possibility that Gli3rep had a negative impact on osteoblast
differentiation by posttranslationally interfering with the function
of osteogenesis-related transcription factors.
To test this hypothesis, we examined the effect of Gli3rep on
the transcriptional activities of Runx2, b-catenin-LEF1, Smad1,
Smad3, and Osterix using luciferase reporter plasmids driven
by the osteocalcin promoter (1050 Oc), LEF-binding site (Top-
flash), Smad1-responsive elements (123GCCG), Smad3-re-
sponsive elements (93CAGA), and type I collagen promoter
(2.3 kb Col1a1), respectively. Gli3rep repressed the transcrip-
tional activities of Runx2 and b-catenin-LEF1 complex and
enhanced that of Smad3. On the other hand, Gli3rep did not alter
the transcriptional activities of Smad1 or Osterix (Figure 4C).
Among Runx2, LEF1, and Smad3, we focused on characterizing692 Developmental Cell 14, 689–699, May 2008 ª2008 Elsevier Inc.
Developmental Cell
Ptch1 Haploinsufficiency and Adult Bone MassFigure 3. Constitutive Activation of
Hh-Ptch1 Signaling and Alteration of Gli3
Processing in OPs from WT and Ptch1+/
Littermates
(A) mRNA expression of Hh-Ptch1 signaling medi-
ators in OPs cultured for 10 days in a-MEM/10%
FBS, determined by real-time RT-PCR analysis.
Data are means ± SDs of triplicate wells, and rep-
resentative data of independent experiments are
shown.
(B) Protein expression of endogenous Gli3 in OPs
cultured for 10 days in a-MEM/10% FBS. Expres-
sion was analyzed by immunoblot analysis using
specific antibodies. Quantification of their band in-
tensities was performed by normalization to those
of actin in each group, and the data are shown
below the pictures. Gli-83/Gli-190, relative band
intensity of Gli-83 to Gli-190 in each group.
(C) Localization of endogenous Gli3 and Runx2 in
WT OPs cultured for 10 days in a-MEM/10%
FBS. IB, immunoblot; Cytosol, cytosol fraction;
Nuclear, nuclear fraction. For (B) and (C), the posi-
tions of full-length (Gli-190) and processed (Gli-83)
Gli3 proteins are denoted by arrows.the interaction between Runx2 and Gli3rep, because the inhibi-
tory action of Gli3rep on Wnt-mediated transcription (Ulloa
et al., 2007) and the interaction between Gli3rep and Smad3
(Liu et al., 1998) have already been reported. The repressive ef-
fect of Gli3rep on Runx2-dependent transcription is not affected
by the presence or absence of Cbfb, the most potent cofactor of
Runx2 (Figure 4C), suggesting that Gli3rep exerts its effect
through Runx2 but not through Cbfb. We next performed lucifer-
ase assays using a series of deletion constructs of the osteocal-
cin promoter (962, 647, 442, 230, 63OSE2) to identify
regions responsible for the transcriptional inhibition by Gli3rep.
In all constructs, Gli3rep repressed the Runx2-dependent tran-
scriptional activity, suggesting that the response region for
Gli3rep was located within the OSE2 site (Figure 4D). Computer
analysis of the OSE2 sequence identified a putative Gli-binding
site (Gli-BS), which partly overlapped with the Runx2-binding
site. Mutations of the Gli-BS in OSE2 diminished the repression
by Gli3rep (Figure 4E), suggesting that the Gli-BS in OSE2 is re-
sponsible for Gli3rep’s repressive effect on Runx2-dependent
transcription.
To investigate the specificity of repression of Runx2-depen-
dent transcription by Gli3rep, we compared the repressive ef-
fects of Gli1, Gli2, Gli3full, andGli3rep. In a luciferase assay using
63OSE2, only Gli3rep, and not the other Glis, had a repressive
effect on Runx2-dependent transcription (Figure 5A). The func-
tions of the Gli vectors used here were verified by their effects
on 83Gli-BS Luc as previously reported (Sasaki et al., 1999) (Fig-
ure 5A). EMSA using nuclear extracts of Glis-transfected cells
revealed that only Gli3rep could bind to OSE2 (Figure 5B, lanes
1–16). The DNA-binding activity of Runx2 was attenuated in cells
transfected with Runx2 and Gli3rep, as compared to Runx2-
transfected cells (Figure 5B, lanes 9 and 13–16). At the same
time, Gli3rep’s binding activity to Gli-BS in the Ptch1 promoterDsequence was maintained (Figure 5B, lanes 20–25), suggesting
that the experimental conditions did not affect the original func-
tion of Gli3rep. Competition binding assays using unlabeled-WT
or -mutated probes showed that Runx2 and Gli3rep bound to
their binding sites within OSE2, which partly overlapped (Fig-
ure 5B, lanes 13 and 17–19). Furthermore, when the nuclear
extract of Gli3rep-transfected cells was added to the binding
mixture containing the extract of Runx2-transfected ones, DNA
binding of Runx2 was inhibited in a dose-dependent manner,
with increasing DNA binding of Gli3rep (Figure 5C). Similarly,
the addition of the recombinant Gli3rep protein to the binding
mixture caused inhibition of DNA binding of Runx2 in a dose-
dependent manner, and the addition of anti-Gli3 antibody atten-
uated the inhibition by Gli3rep (Figure S7). On the other hand,
Gli3rep did not affect DNA binding by the LEF1-b-catenin com-
plex or the Smad3-Smad4 complex (Figure S8), although it did
alter their transcriptional activities (Figure 4C), arguing against
the possibility that the inhibitory effect of Gli3rep on DNA binding
of Runx2was nonspecific. To explore this inhibitory effect further
in a genomic DNA context, we performed chromatin immunopre-
cipitation (ChIP) of extracts isolated from C3H10T1/2 cells trans-
fected with Runx2, Gli3rep, or both. As shown in Figure 5D,
recruitment of Gli3rep onto OSE2 in the osteocalcin promoter
was readily detected, and that of Runx2 was decreased by
cotransfection of Gli3rep. In addition, a physical association be-
tween Runx2 and Gli3rep was not discernible in our experiments
(data not shown). Finally, we examined the DNA binding activity
of Runx2 inGli3/ and Ptch1+/OPs by EMSA. The activity was
augmented in both mutants as compared to WT littermates
(Figure 5E), supporting our findings so far about the overexpres-
sion of Gli3rep. These lines of evidence suggest that Gli3rep
attenuates Runx2 transcriptional activity by competitively inhib-
iting DNA binding of Runx2 to OSE2, and that excessiveevelopmental Cell 14, 689–699, May 2008 ª2008 Elsevier Inc. 693
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partly attributable to the reduction of this attenuation.
Systemic Interference with Hh Signaling Decreases
Bone Mass in Adult Mice
The data so far reveal that the activation of Hh signaling by Ptch1
haploinsufficiency causes an increase in adult bone mass, rais-
ing the possibility that blocking Hh signalingmay have a negative
impact on adult bone mass. To evaluate this effect, we system-
ically treated WT mice (8 weeks of age) with cyclopamine, a Hh
signaling blocker, and analyzed their skeletal system in compar-
ison with the mice treated with tomatidine, a steroidal alkaloid
similar to cyclopamine but without any effects on Hh signaling.
After 1 month of treatment, the cyclopamine-treated mice
showed a reduction in mRNA expression of Ptch1 and Gli1 in
bone, indicating that Hh signaling was inhibited (Figure 6A). Their
bone mass and bone mineral density were significantly lower
than in the tomatidine-treated group, whereas there was no
significant difference in body weight (Figures 6B and 6C). Histo-
logical and bone histomorphometric analyses revealed a
decrease in bone volume in the cyclopamine-treated group,
which was attributed to impaired osteoblast differentiation and
function (Figures 6D and 6E). As for bone resorption, the number
of TRAP-positive osteoclasts and values of all parameters for
bone resorption were decreased in the cyclopamine-treated
mice (Figures 6D and 6E). Taken together, these findings
Figure 4. Repression of Runx2-Dependent
Transcription by Gli3 Repressor Form
(A) ALP and von Kossa stainings in cultures of cal-
varial cells from WT and Gli3/. For ALP staining,
cells were cultured for 14 days in a-MEM/10%
FBS with DMSO or Hh agonist (Hh-ago). For von
Kossa staining, cells were cultured for 28 days in
a-MEM/10% FBS containing dexamethasone, b-
glycerophosphate, and ascorbic acid phosphate,
with DMSO or Hh-ago. Representative pictures
of independent experiments are shown.
(B) Osteocalcin mRNA expression determined by
real-time RT-PCR analysis in WT OPs and in
C3H10T1/2 cells. WT OPs were cultured for 7
days in a-MEM/10% FBS after infection with ade-
noviruses expressing GFP, GLI3, and GLI3rep.
C3H10T1/2 cells were cultured for 2 days in
DMEM/10% FBS after transfection with the indi-
cated plasmids.
(C) Effects of GLI3rep on transcriptional activities
of Runx2 (1050 Oc Luc), LEF1-b-catenin (Top-
flash), Smad3 (93CAGA Luc), Smad1 (123GCCG
Luc), andOsterix (2.3 kbCol1a1 Luc). NIH3T3 cells
(1050Oc, Topflash, 93CAGA, and123GCCGLuc)
or C3H10T1/2 cells (2.3 kbCol1a1 Luc) were trans-
fected with each reporter plasmid, in combination
with the indicated plasmids, and a luciferase assay
was performed 48 hr after transfection. caLEF-1,
constitutively active lymphoid enhancer factor-1;
caTbr, constitutively active transforming growth
factor-b receptor type I; caBmpr1a, constitutively
active BMP receptor type IA.
(D) Transcriptional activity repressed by GLI3rep
in deletion mutants of the osteocalcin promoter.
Deletion mutants of the osteocalcin promoter of
the indicated lengths (962, 647, 442, and 230 bp)
were constructed from the 1050 Oc Luc. NIH
3T3 cells were transfected with each mutant
reporter plasmid or 63OSE Luc, in combination
with the indicated plasmids.
(E) The effect of mutation in OSE2 on GLI3rep-
mediated repression of Runx2-dependent tran-
scriptional activation. The indicated mutation
was created in the Runx2-binding site or putative
Gli-binding site of the 230 Oc Luc. NIH 3T3 cells
were transfected with each reporter plasmid, in
combination with the indicated plasmids. For
(B)–(E), data are means ± SDs of triplicate wells,
and representative data of independent experi-
ments are shown.694 Developmental Cell 14, 689–699, May 2008 ª2008 Elsevier Inc.
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DNA Binding Activity by Gli3 Repressor
Form
(A) Comparison of transcriptional activity of the
Gli family proteins (Gli1, 2, 3 and 3rep) using 83
Gli-binding site Luc (left, 8330Gli-BS Luc) and
63OSE2 Luc (right). C3H10T1/2 cells were trans-
fected with each reporter plasmid, in combination
with the indicated plasmids. Data are means ±
SDs of triplicate wells, and representative data of
independent experiments are shown.
(B) Binding of Gli3rep to OSE2 determined by
EMSA. Oligonucleotide probes containing OSE2
and ones containing the Gli-binding site in human
PTCH1 promoter were used (top). The Runx2-
binding sequence is in boldface, and the putative
Gli-binding sequence is underlined. Nuclear ex-
tracts of COS-7 cells transfected with the indi-
cated plasmids were analyzed using DIG-labeled
OSE2 probes (bottom, left) and Gli-BS ones
(bottom, right). Arrows, shifted bands of Runx2-
DNA complexes; Arrowheads, shifted bands of
Gli3rep-DNA complexes.
(C) Inhibitory effect of GLI3rep on DNA binding ac-
tivity of Runx2. Nuclear extracts of Runx2-trans-
fected COS-7 cells were analyzed by EMSA using
DIG-labeled OSE2 probes. Increasing amounts
(13, 23, and 43) of nuclear extracts of GLI3rep-
transfected COS-7 cells (GLI3rep-NE) or equiva-
lent amounts of those of GFP-transfected COS-7
cells (GFP-NE) were added to the DNA binding re-
action mixture. Arrow, shifted bands of Runx2-
DNA complexes. Arrowhead, shifted bands of
Gli3rep-DNA complexes.
(D) Recruitment of GLI3rep onto endogenous os-
teocalcin promoter. ChIP assay was performed
on C3H10T1/2 cells cultured for 2 days after trans-
fection with the indicated plasmids. In, PCR from
total DNA input for each sample; IgG, PCR from
the immunoprecipitation product with normal IgG
(negative control); a-H3, PCR from the immuno-
precipitation product with anti-acetyl histon H3
(positive control); mOG2 mouse osteocalcin gene
2; E IV, coding region in exon 4.
(E) DNA binding activity of Runx2 in Gli3/ or
Ptch1+/ OPs. Nuclear extracts of OPs derived
from WT and Gli3/ littermates (left) or WT and
Ptch1+/ ones (right) were analyzed by EMSA us-
ing DIG-labeled OSE2 probes. As a negative con-
trol, a binding mixture containing COS-7 nuclear
extracts and labeled probes was loaded in lane
1. Arrows, shifted bands of Runx2-DNA com-
plexes. For (C) and (E), quantified intensities of
shifted bands of Runx2-DNA complexes are
shown below each panel.suggest that systemic interferencewith Hh signaling causes low-
turnover osteopenia in adult mice, showing the importance of
Hh-Ptch1 signaling in adult bone homeostasis.
DISCUSSION
The present study had five major findings. First, Ptch1 haploin-
sufficiency caused increased bone mass with enhanced osteo-
blast differentiation. Second, generation of endogenous Gli3rep
was repressed in Ptch1+/ OPs with the activation of Hh-Ptch1signaling, and Gli3rep, but not Gli3full, was preferentially local-
ized in the nucleus. Third, Gli3rep attenuated Runx2 transcrip-
tional activity by competitively inhibiting its DNA binding. Fourth,
in both Gli3/ and Ptch1+/ cells, the DNA-binding activity of
Runx2 was augmented. Finally, systemic interference with Hh
signaling using an inhibitor resulted in decreased bone mass in
adult mice. These findings suggest that Hh-Ptch1 signaling reg-
ulates adult bone mass and that this regulation occurs at least
partly through modulation of the effect of Gli3rep on osteo-
blast-related transcription factors.Developmental Cell 14, 689–699, May 2008 ª2008 Elsevier Inc. 695
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Ptch1 Haploinsufficiency and Adult Bone MassBone mass phenotypes in Ptch1+/ mice indicate that
Hh-Ptch1 signaling has crucial roles not only in forming embry-
onic bone but also in maintaining adult bone mass. This notion
is in harmony with the recent report by Maeda and colleagues
that indicates the involvement of Ihh produced by postnatal
chondrocytes in sustaining the trabecular bone (Maeda et al.,
2007). Moreover, we demonstrate that the direct input of Hh
signaling to postnatal skeletal cells affects the bone mass
and that Ptch1, a key mediator of various fundamental pro-
cesses in embryonic development, also controls bone homeo-
Figure 6. The Effect of Administration of Hh
Signaling Inhibitor on Adult Bone Mass
(A) mRNA expression of Ptch1 andGli1 in bone tis-
sue, determined by real-time RT-PCR analysis.
Data are means ± SDs of triplicate samples.
(B) Plain X-ray images of the femurs (left) and tibias
(right) of representative tomatidine-treated and
cyclopamine-treated mice.
(C) Bone mineral density of the whole femurs and
tibias (upper) and body weight (lower) of tomati-
dine-treated and cyclopamine-treated mice.
Data are means ± SDs of five mice per treatment.
*p < 0.05 versus tomatidine-treated mice.
(D) von Kossa staining, TRAP staining, and calcein
double labeling of the proximal tibia sections of
representative tomatidine-treated and cyclop-
amine-treated mice. Bar, 300 mm.
(E) Histomorphometric analyses of bone volume
and bone formation parameters in the proximal
tibia of tomatidine-treated and cyclopamine-
treated mice. Data are means ± SDs of five mice
per treatment. *p < 0.05 versus tomatidine-treated
mice.
stasis in adult tissue. In the accompany-
ing paper, Mak et al. (2008) (in this issue
of Developmental Cell) report the skele-
tal phenotype of the mice in which
Ptch1 is disrupted selectively in mature
osteoblasts. In common with our find-
ings on conventional mutant mice, both
osteoblastogenesis and osteoclastogen-
esis were enhanced in their mice, sug-
gesting that the activation of Hh-Ptch1
signaling directly induced osteoblasto-
genesis and indirectly induced osteo-
clastogenesis via mature osteoblasts.
However, their mice showed the oppo-
site phenotypes to ours in terms of
bone mass, with bone resorption domi-
nant over bone formation. It is not
entirely clear why such a difference
arose between their mice and ours, par-
ticularly considering the similar changes
observed at a cellular level, but a number
of factors could be involved. First, the
level of modulation of Hh-Ptch1 signaling
was different between our study and
theirs; ours was a partial modulation
(haploinsufficiency mutants and sys-
temic administration of small compounds), while theirs was
full (homozygous mutants). It is possible that partial modulation
of the Hh-Ptch1 signaling has a dominant impact on bone for-
mation, while full modulation acts dominantly on bone resorp-
tion. Second, our mice were conventional mutants in which all
the cells were affected from the onset of development, while
theirs were conditional ones in which only mature osteoblasts
were affected. Thus, their mice may have highlighted a specific
role of Hh-Ptch1 signaling in mature osteoblasts’ regulation of
osteoclastogenesis.696 Developmental Cell 14, 689–699, May 2008 ª2008 Elsevier Inc.
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Ptch1 Haploinsufficiency and Adult Bone MassExpression of Gli1 mRNA was increased in Ptch1+/ OPs,
indicating constitutive activation of Hh signaling. In contrast,
Ptch1mRNA was decreased in Ptch1+/OBs. In line with our re-
sults, Goodrich and colleagues reported that Ptch1 mRNA was
reduced inPtch1+/ cerebella despite high-level Ptch1 transcrip-
tion shown by increased expression of LacZ fused to Ptch1 al-
leles (Goodrich et al., 1997). In a physiological context, high-level
Ptch1 in response to Hh has been known to limit the effects of Hh
signaling by intracellularly attenuating its continuous activation
or by preventing its transmission across the cells (Goodrich
et al., 1997). Taking these findings together, we speculate that
enhanced transcription of Ptch1 by Hh signaling activation can-
not overcome the lack of one copy of the Ptch1 gene, because
the negative feedback loop collapses. As a result, low-level
Ptch1 may further accelerate the constitutive activation of Hh
signaling in Ptch1+/ cells.
We focusedonGli3 as a keydownstreammediator ofHh-Ptch1
signaling in osteoblast differentiation for the following reasons.
First, as mentioned in the Introduction, a number of reports indi-
cate that Gli3 mainly acts as a transcriptional repressor and that
this repressor function regulated by the Hh input has a crucial
role in limb development. Second, Ihh/ developing limbs
showedhigherGli3expression thanWT (Hilton et al., 2005). Third,
as a consequence of Hh-Ptch1 signaling activation,Gli3 expres-
sion and Gli3rep generation were remarkably repressed in
Ptch1+/OPs. Fourth,Gli3/ calvarial cells spontaneously differ-
entiated into osteoblasts and barely responded to a Hh agonist.
Although Gli3full was reported to have an activator function in
some contexts, Gli3full was preferentially localized in the cyto-
plasmofOPs.Furthermore, overexpressedGli3full that hadaccu-
mulated in the nucleus had no effect on the transcription of osteo-
calcin mRNA. These findings suggest that Gli3full does not have
a major role in the transcription of osteogenesis-related genes.
The role of Gli2 in skeletal development and the positive effect
on osteoblast differentiation documented by other researchers
(Miao et al., 2004; Mo et al., 1997; Shimoyama et al., 2007; Zhao
et al., 2006) raise the possibility that Gli2 might play a role in the
effect of Ptch1 haploinsufficiency on osteoblast differentiation.
However, we think it unlikely that Gli2 is a main mediator, at least
in Ptch1 haploinsufficiency, because no alteration of Gli2 expres-
sion, localization, or processing was observed between Ptch1+/
andWTOPs. Supporting our findings, the expression level ofGli2
in the Ihh/perichondriumwasreported tobecomparable to that
in WT (Hilton et al., 2005). On the other hand, our findings seem
inconsistent with reports that overexpressed Gli2 in C3H10T1/2
cells translocated into the nucleus upon Ihh treatment (Shi-
moyama et al., 2007) or with reports that Shh treatment of fibro-
blasts suppressed endogenous Gli2 processing and degradation
(Pan et al., 2006). Our findings also may not concur with the
reports that Gli2 induced Bmp2 expression and that Gli3rep re-
pressed the expression (Garrett et al., 2003; Zhao et al., 2006),
while we showed that endogenous Bmp2 expression was not
markedly upregulated in Ptch1+/. Discrepancies between our
findings and others described so far may arise from differences
of cell types (primary cells versus cell lines; osteoblasts versus
fibroblasts). Alternatively, Ptch1 haploinsufficiency may lead to
less activation of Hh signaling or less alteration of Gli expression
than treatmentwithHh proteins or overexpresion ofGli. It remains
to be determined whether Hh-Ptch1 signaling induces osteoblastDdifferentiation through Gli2. Analysis of the effect of Hh treatment
on Bmp2 expression, Runx2 function, and osteoblast differentia-
tion in Gli2 knockout cells may help address this question.
Regarding BMP and Hh-Ptch1 signaling, we also demon-
strated that responsiveness to exogenous BMP2 was increased
in Ptch1+/ cells compared to WT cells. In line with our results,
Hh-Ptch1 signaling has been shown to modify cellular respon-
siveness to other signals, including several members of the
BMP family (Murtaugh et al., 1999). Based on our findings, we in-
fer that, in osteogenesis, Hh-Ptch1 signalingmodifies the cellular
responsiveness to BMP by regulating Gli3’s antagonistic actions
against Runx2.
To determine howGli3rep attenuated the transcriptional activ-
ity of Runx2, we considered four potential mechanisms of the
attenuation (Latchman, 1996): (1) squelching of the basal tran-
scriptional machinery, (2) prevention of DNA binding of Runx2,
(3) quenching of the transactivation properties of DNA-bound
Runx2, and (4) recruitment of a corepressor. By EMSA and
ChIP, we demonstrated specific binding of Gli3rep to OSE2
and Gli3rep’s inhibitory effect on the DNA binding of Runx2. In
addition, physical interaction between Runx2 and Gli3rep was
not discernable. Based on these results, we propose that Gli3rep
represses Runx2 by competitively preventing its DNA binding.
Squelching does not appear to be the mechanism, because
Gli3rep failed to repress the basal activity of Oc-luc. On the other
hand, Gli3rep was reported to interact with the histone deacety-
lase 1 (HDAC1) and the Ski corepressor (Dai et al., 2002), raising
the possibility that Gli3rep may regulate transcription by revers-
ing chromatin remodeling and/or recruiting corepressors. Al-
though further work is needed, we suggest that this may not be
the main mechanism of Runx2 attenuation by Gli3rep because
we observed strong attenuation of Runx2-induced transcription
by Gli3rep in the luciferase assays, in which exogenous plasmids
typically do not assume the normal chromatin structure, and
therewas nomarked alteration in histoneH3 acetylation byChIP.
Our findings may not concur with a recent report by Shi-
moyama and colleagues in which in vitro data indicated that
overexpressed Gli2 enhanced Runx2 function through physical
interaction (Shimoyama et al., 2007). The discrepancy may arise
from the difference in the structures of reporter constructs. How-
ever, the physiological role of Gli2 in Ptch1+/ seems unclear,
because no alteration of Gli2 expression, localization, or pro-
cessing was observed between Ptch1+/ and WT OPs.
In conclusion, we have identified Hh-Ptch1 signaling as a cru-
cial regulator of postnatal bone homeostasis. Alteration of Hh-
Ptch1 signaling due to genetic anomaly or drugs may affect
bone mass in patients at any age. Based on our study and that
of Mak et al. (2008), it is clear that Hh-Ptch1 signaling can be
a potential molecular target for the treatment of osteoporosis.
At the same time, in the modulation of Hh-Ptch1 signaling, it is
necessary to consider the level of the modulation, as well as
the target cells and timing, because those factors may signifi-
cantly influence the outcome.
EXPERIMENTAL PROCEDURES
Animal Experiments
Ptch1tm1Mps (Ptch+/) and Gli3Xt-J (Gli3+/) mice were obtained from Jackson
Laboratory (Bar Harbor, ME); wild-type C57BL/6N mice were obtained fromevelopmental Cell 14, 689–699, May 2008 ª2008 Elsevier Inc. 697
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Ptch1 Haploinsufficiency and Adult Bone MassCharles River Japan (Kanagawa, Japan). Histological, histomorphometric, and
radiological analyses were performed as described (Kugimiya et al., 2005). NIH
Image was used to measure the ratio of the trabecular bone area to the total
area. In cyclopamine treatment ofmice, cyclopamine and tomatidine (BIOMOL
International, Plymouth Meeting, PA) were dissolved in a solution of 45% of
2-hydroxypropyl-b-cyclodextrin (HBC, Sigma-Aldrich) in PBS at 1 mg/ml, as
described (Sanchez and Ruiz i Altaba, 2005). Mice received intraperitoneal in-
jections of either 10mg/kg of HBC-cyclopamine or HBC-tomatidine beginning
at 8 weeks of age and every day thereafter for a month. All experiments were
performed on male mice in accordance with the protocol approved by the
Animal Care and Use Committee of the University of Tokyo.
Cell Culture
NIH 3T3, COS-7, and C3H10T1/2 cells were obtained from the RIKEN Cell
Bank (Tsukuba, Japan). Isolation of bone marrow stromal cells from long
bones or of osteoblast precursors from calvaria, osteogenic culture (Ogata
et al., 2000; Akune et al., 2004), in vitro osteoclast formation from BMMfs (Ka-
tagiri et al., 2006) or RAW264.7 cells (Ogasawara et al., 2004a), and the cocul-
ture of OPs and BMMf (Akune et al., 2004; Ogata et al., 2000) were performed
as described. Cell proliferation was quantified using a Cell Counting Kit-8
(Wako Pure Chemical Industry, Osaka, Japan). Recombinant human (rh)
BMP2 and Hh agonist (Cur-0199567; Frank-Kamenetsky et al., 2002) were
used at 200 ng/ml and 10 nM, respectively. Plasmid transfection was per-
formed using FuGENE6 (Roche, Penzberg, Germany); adenoviruses were
infected at 50 MOI (multiplicity of infection). Alkaline phosphatase (ALP) and
von Kossa stainings were performed as described (Kugimiya et al., 2005).
Real-Time RT-PCR
Total RNA extraction, reverse-transcription, and real-time PCR were per-
formed as described (Kugimiya et al., 2005). All reactions were run in triplicate.
The primer sequences are available upon request.
Luciferase Assay
Cells were plated onto 24-well plates and transfected with 0.4 mg of DNA
mixture containing the test reporter plasmids, the control reporter plasmids
encoding Renilla luciferase, and the effector plasmids. The dual luciferase as-
say was performed 48 hr after transfection as described (Yano et al., 2005).
Immunoblot and Coimmunoprecipitation
Whole-cell lysates were isolated using RIPA buffer as described (Ogasawara
et al., 2004b). Separated extraction of cytoplasmic and nuclear proteins was
performed using the NE-PER Kit (Pierce Chemical, Rockford, IL). SDS-PAGE
and immunoblotting were performed as described (Yano et al., 2005). Band in-
tensities were calculated using Quantity One (Bio-Rad Laboratories, Hercules,
CA). Coimmunoprecipitation was performed using the Catch and Release Kit
(Upstate, Lake Placid, NY) and 2 mg of specific antibodies.
ChIP
ChIP was performed using EZ ChIP (Upstate). PCR was performed to amplify
the promoter region (86/285) and the coding region (exon 4) of the mouse
osteocalcin.
EMSA
Nuclear extracts were obtained as described (Dignam et al., 1983). hGLI3rep
protein was translated in vitro using TNT Quick Coupled Transcription/Trans-
lation Systems (Promega, Madison, WI) and pCITE-4a vectors (Novagen,
Darmstadt, Germany). Digoxigenin (DIG)-labeled probes were constructed
using the DIG Gel Shift Kit (Roche).
Statistical Analysis
The means of groups were compared by ANOVA, and the significance of
differences was determined by post hoc testing using Bonferroni’s method.
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